HYPD

Business Context and Reporting Period

Company: Eyenovia, Inc. (Note: Input metadata referenced "HYPERION DEFI, INC.", but the filing text confirms the registrant is Eyenovia, Inc., trading as EYEN on Nasdaq).

Reporting Period: Fiscal year ended December 31, 2024.

Overview: Eyenovia is an ophthalmic technology company developing the Optejet® microdose delivery platform. In November 2024, the company received negative clinical trial results for its MicroPine product (myopia treatment), leading to a strategic restructuring. The company has paused the national sales rollout of its commercial products (Mydcombi® and clobetasol propionate) to conserve cash while exploring strategic alternatives, including a potential business combination with Betaliq, Inc. (announced March 2025).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Minimal revenue recognized ($57k) compared to prior year ($3.8k), primarily from product sales of Mydcombi and clobetasol propionate.
• Cost of Revenue: Increased significantly to $3.9 million due to a $3.1 million inventory write-down driven by uncertainty regarding commercial products and strategic alternatives.
• Asset Impairments: Recorded $11.2 million in impairments in 2024 (none in 2023), including $6.1 million in intangible assets (Formosa license) and $2.5 million in property and equipment.
• License Reacquisition: Incurred $4.9 million in expenses to reacquire rights to the MicroPine program from Bausch + Lomb.
• Workforce Reduction: Implemented a reduction in force affecting approximately 75% of the workforce, with estimated severance costs of $0.3 million.
• Stock Split: Effected a 1-for-80 reverse stock split on January 31, 2025, to regain Nasdaq compliance.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing includes a "going concern" explanatory paragraph. Management states there is substantial doubt about the company's ability to continue as a going concern for at least one year without additional capital. Cash on hand ($2.1M) is insufficient to fund operations.
• Strategic Alternatives: The company is actively evaluating strategic options, including a business combination, reverse merger, or asset sales. A non-binding Letter of Intent was signed with Betaliq, Inc. in March 2025 for a proposed reverse merger.
• Debt Obligations: The company owes approximately $10.2 million (principal and accrued interest) to Avenue Capital Management. Payments have been deferred until September 2025 under a Second Amendment. Failure to secure additional funding or a strategic transaction could lead to default.
• Product Status:
  • MicroPine: Development halted following negative Phase III CHAPERONE study results.
  • MicroLine: Presbyopia program placed on hold due to deteriorating market opportunity.
  • Mydcombi & Clobetasol: Commercial sales paused pending additional funding.
  • Optejet UFD: Development accelerated; targeting a 510(k) submission in Q4 2025.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting related to the valuation of equity shares issued for licensing agreements and the impairment of right-of-use assets.

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $2.1 million cash balance against the current burn rate and the timeline for the proposed Betaliq transaction.
• Debt Covenants: Review the specific terms of the Avenue Loan amendments, particularly the requirement to use 65-75% of future ATM offering proceeds to pay down debt.
• Strategic Transaction Status: Monitor the progress of the non-binding Letter of Intent with Betaliq, Inc., including the likelihood of closing a definitive agreement and obtaining stockholder approval.
• Inventory Valuation: Assess the remaining inventory value given the $3.1 million write-down and the pause in commercial sales.
• Internal Control Remediation: Evaluate the company's plan to remediate the identified material weaknesses in financial reporting.